Jazz Pharmaceuticals plc (JAZZ) Stock: Price, Forecast & Analyst Target
Jazz Pharmaceuticals plc (JAZZ) — MoonshotScore 40/100 (Weak band), calculated Nov 18, 2026. Price $247.77 (+2.93%), as of the Nov 18, 2026 trading session; market cap $15.9B.
Educational signal · not a buy or sell recommendation · How to read this
Jazz Pharmaceuticals plc · JAZZ · NASDAQ · Healthcare · Biotechnology
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered): Jazz Pharmaceuticals is a commercial drugmaker focused on sleep disorders, severe epilepsies and selected cancers. Its revenue base rests chiefly on Xywav and Epidiolex or Epidyolex, with hematology and oncology products providing additional breadth. The durability question is whether rare-sleep growth and newer medicines can reduce product concentration while supporting a debt load that remains above cash.
Price as of Nov 18, 2026
Key Statistics
MoonshotScore v2 · Jazz Pharmaceuticals (JAZZ)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and durable growth. The score also carries a risk penalty for reported profit not backed by cash flow. Business Quality: Elite; Financial Safety: Okay; Valuation: Fair; Growth Durability: Growing; Momentum: Surging.
- EPS beat 5 of the last 8 reports
- Altman Z 1.96 · Piotroski F 7
- ROE 4.6% · ROA 1.7% · current ratio 1.82 · earnings yield 1.3% · free-cash-flow yield 10.2%
Helping: business quality, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 39 | Weak | |
| 39 | Weak | |
| 38 | Weak | |
| 38 | Weak | |
| 40 | Weak | |
| 40 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $247.77 | |
| Change on the day | +2.93% | |
| 52-week range | $156.95–$266.38 | |
| Market capitalisation | $15.9B | — |
| Price / earnings (trailing) | 67.24 | |
| Shares traded on the day | 721.5K | |
| Beta (volatility vs the S&P 500) | 0.32 |
Price & events
Point at or tab to any week for its close.
Other perspectives
Council score for Jazz Pharmaceuticals (JAZZ): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
3 lenses, 3 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 20, 2026
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 18, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 18, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Jazz Pharmaceuticals (JAZZ), and what does it report?
Short answer · as of
Jazz sells prescription medicines to narrowly defined patient populations rather than relying on a discovery platform without commercial products.
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
Reported revenue largely measures sales of named therapies, supplemented by a separately disclosed oxybate royalty stream, while the development portfolio represents potential future indications and products.
Xywav is the largest disclosed revenue source, followed by Epidiolex or Epidyolex, while Rylaze or Enrylaze and Zepzelca add hematology and oncology exposure. The pipeline extends into additional solid tumors, blood cancers, glioma and epilepsy, so research spending supports a broader set of opportunities than the current revenue mix suggests.
What do the latest results show for Jazz Pharmaceuticals (JAZZ)?
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
Revenue rose from the preceding period and reached the upper end of the disclosed quarterly run. Operating profit also increased, but net income and diluted earnings declined as research spending climbed materially.
Revenue exceeded expectations at the latest release while earnings fell short, a different pattern from the preceding release when each surpassed expectations. Management continues to expect Xywav growth and has issued a rare-sleep revenue outlook, but product sales must still substantiate that guidance.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | Not available | Not available | Not available | Not available |
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Sep 2026 | $1.24B | -$483M | -$7.47 (diluted) |
| Q2 FY2026 | $1.21B | $193M | $2.78 (diluted) |
| Q1 FY2026 | $1.07B | $293M | $4.43 (diluted) |
| Q4 FY2025 | $1.20B | $203M | $3.34 (diluted) |
What are the financial strengths and risks for Jazz Pharmaceuticals (JAZZ)?
Short answer · as of
Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
Established products generate substantial cash: operating cash flow has remained positive throughout the disclosed quarterly series, while capital spending has generally been modest beside that inflow. Trailing margins and free-cash-flow yield likewise reflect a profitable commercial portfolio, even though annual net results have moved between profit and loss.
Jazz is not a net-cash business. Debt exceeds cash and investments, and liquidity ended below its level at the start of the reported window despite continued operating inflows. A setback in Xywav demand or sustained spending on programs that fail to become meaningful products would therefore compete with debt reduction and future reinvestment.
What should you watch next at Jazz Pharmaceuticals (JAZZ)?
Short answer · as of
Current published price targets run low $220.00 · high $337.00 · consensus $295.73 · median $300.00 against a quoted price of $247.77 (as of Nov 18, 2026).
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
At the scheduled earnings update, track Xywav against management’s rare-sleep outlook, then examine whether Epidiolex or Epidyolex, Rylaze or Enrylaze and Zepzelca are making the revenue mix less dependent on the sleep franchise. The recent revenue beat sets a demanding comparison, while the accompanying earnings miss makes expense discipline equally important.
Revenue growth alone will not settle the issue. Operating profit, research spending, cash conversion and the movement of cash relative to debt will show whether commercial momentum is strengthening financial flexibility. Consensus estimates assume continued revenue and earnings expansion across the forecast horizon, leaving product-level execution as the evidence that matters.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
- The next earnings date is not yet scheduled in the calendar we read.
Checked against the records this page reads, on the dates shown above.
How does Jazz Pharmaceuticals compare with its peers?
Short answer
Jazz Pharmaceuticals's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered).
Jazz occupies a middle ground between mature specialty pharmaceutical companies and development-focused biotechnology businesses. It already has profitable, cash-generating franchises that can finance a wide clinical slate, yet its economics remain more concentrated in named therapies than those of a broadly diversified drugmaker.
A distinctive feature is the pairing of direct Xywav sales with a separate royalty stream from a high-sodium authorized generic oxybate product. Epidiolex or Epidyolex adds severe-epilepsy exposure, while Rylaze or Enrylaze and Zepzelca bring different cancer settings; comparisons therefore depend more on indication-specific commercial execution than on pipeline size alone.
| Company | Price | Market value | Score |
|---|---|---|---|
| $68.29 Nov 18, 2026 | $16.7B | 98 5-pillar Nov 18, 2026 | |
| $577.34 Nov 18, 2026 | $24.6B | 97 5-pillar Nov 18, 2026 | |
| $270.33 Nov 18, 2026 | $17.7B | 96 5-pillar Nov 18, 2026 | |
| $315.34 Nov 18, 2026 | $9.34B | 96 5-pillar Nov 18, 2026 | |
| $162.86 Nov 18, 2026 | $16.5B | 95 5-pillar Nov 18, 2026 | |
| $95.80 Nov 18, 2026 | $10.9B | 95 5-pillar Nov 18, 2026 | |
| $72.75 Nov 18, 2026 | $11.4B | 92 5-pillar Nov 18, 2026 | |
| $117.80 Nov 18, 2026 | $24.0B | 91 5-pillar Nov 18, 2026 | |
| $66.12 Nov 18, 2026 | $9.99B | 90 5-pillar Nov 18, 2026 | |
| $149.40 Nov 18, 2026 | $20.0B | 72 5-pillar Nov 18, 2026 | |
| $83.83 Nov 18, 2026 | $7.34B | 53 5-pillar Nov 18, 2026 | |
| Jazz Pharmaceuticals (JAZZ) — this page | $247.77 | $15.9B | 40 |
| $398.08 Nov 18, 2026 | $9.25B | 35 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $220.00 – $337.00
- Consensus target
- $295.73
- Median target
- $300.00
Consensus record · Captured .
Measured against a quoted price of $247.77 (as of Nov 18, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 6, 2026
- Transactions
- 86
- Identified insiders
- 18
- Purchases
- 0
- Sales
- 25
- Other transactions
- 61
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held JAZZ in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.15% | $33.61M | New position |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Jazz Pharmaceuticals (JAZZ)?
What Investors Ask About Jazz Pharmaceuticals (JAZZ) — Healthcare
Research dated 2026-09-13 (results through Q2 FY2026; the quarter ended Sep 2026 not covered); the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why is Xywav so important to Jazz Pharmaceuticals?
Xywav is Jazz’s largest disclosed revenue stream and anchors management’s rare-sleep outlook. Its growth affects portfolio expansion, cash generation and the company’s capacity to support development spending while carrying net debt.
How does Epidiolex or Epidyolex diversify Jazz?
Epidiolex or Epidyolex sits behind only Xywav among the disclosed revenue streams and serves severe seizure disorders rather than sleep medicine. It gives Jazz a sizable commercial franchise whose demand is tied to different diseases and patients.
What is unusual about Jazz’s oxybate revenue model?
Jazz reports direct Xywav product revenue alongside a separate royalty from a high-sodium authorized generic oxybate product. The company therefore participates in oxybate economics through distinct revenue channels.
Can Jazz’s oncology products offset its sleep concentration?
Rylaze or Enrylaze and Zepzelca already contribute meaningful sales, and newer cancer medicines broaden the commercial and development slate. Their disclosed combined contribution remains below Xywav, so oncology diversification is underway rather than complete.
What is the JAZZ stock price today?
The last price recorded for Jazz Pharmaceuticals plc (JAZZ), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the JAZZ price target?
The analyst consensus price target for Jazz Pharmaceuticals plc (JAZZ), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 25 figures on this page — 1 from SEC filings and earnings calls, 19 from Financial Modeling Prep (FMP), 4 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-13), by section of the research
ETFs that hold JAZZ
Funds in our ETF coverage that list JAZZ among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| Simplify Health Care ETF (PINK) | 3.92% | |
| iShares Focused Value Factor ETF (FOVL) | 2.68% | |
| Alger Russell Innovation ETF (INVN) | 2.52% |